drugset
Drugs / eNOS transfected EPCs
last change Jul 2015 re-read 3 minutes ago

eNOS transfected EPCs

Cell therapy

Developed for
pulmonary hypertension
Investigated by
Northern Therapeutics · Sir Mortimer B. Davis - Jewish General Hospital · Unity Health Toronto

Trials 1

today NCT00469027 · Ph 1
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT00469027 May 2006 → Jul 2012 pulmonary hypertension Northern Therapeutics Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as eNOS transfected EPCs ClinicalTrials.gov intervention name — accepted as the source's own label NCT00469027 ↗
Modality Cell therapy “culture-derived endothelial progenitor cells, transiently transfected with endothelial nitric oxide synthase” PMID 26195220 ↗ Jul 2015
Route Other “delivered into the right atrium via a multiport pulmonary artery catheter” PMID 26195220 ↗ Jul 2015